PTPRC and carcinoma: Non-immunoreactivity for cytokeratin (Figure-3b) ruled out poorly differentiated carcinoma including lung primary, LCA non-immunoreactivity (Figure-3c) ruled out lymphoma and granuloma, nonimmunoreactivity for chromogranin and synaptophysin ruled out paraganglioma, and MART-1 non-immunoreactivity (Figure-3d) ruled out melanoma.